Drug Trial Radar · NCT03686124
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
375
Planned (sponsor's estimate)
Start
May 14, 2019
Primary completion
Dec 2028
Study completion Jun 2032
Sponsor
- Lead sponsor
- Immatics US, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Conditions
- Refractory Cancer
- Recurrent Cancer
- Solid Tumor, Adult
- Cancer
Interventions
IMA203 ProductBiological
The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
IMA203 product- flat doseBiological
The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells
IMA203CD8 ProductBiological
The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
NivolumabDrug
Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.
IMADetect®Device
IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Determine the MTD and/or recommended dose for extension for IMA203/IMA203CD8Time frame: 28 days
- Phase 1 and Phase 2: Number and grade of treatment emergent adverse events and adverse events of special interest in subjects treated.Time frame: 35 days
- Phase 1 and Phase 2: Tumor ResponseTime frame: 5 years
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Stanford Cancer Institute
Stanford, California · Recruiting
University of Colorado, Anschutz Medical Campus
Aurora, Colorado · Recruiting
University of Miami Hospital and Clinics
Miami, Florida · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run
Columbus, Ohio · Recruiting
University of Pennsylvania, Perelamn Center for Advanced Medicine
Philadelphia, Pennsylvania · Recruiting
Thomas Jefferson University, Honickman Center
Philadelphia, Pennsylvania · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie
Berlin, Germany · Recruiting
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany · Recruiting
Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
Klinikum rechts der Isar der Technischen Universität München
Munich, Bavaria, Germany · Recruiting
Universitätsklinikum Würzburg
Würzburg, Bavaria, Germany · Recruiting
Universitätsklinikum Bonn - Medizinische Klinik III
Bonn, North Rhine-Westphalia, Germany · Recruiting
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Rhineland-Palatinate, Germany · Recruiting
Universitätsklinikum C.-G.-Carus Dresden
Dresden, Saxony, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.